Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jul 11;35(7):1095-1098.
doi: 10.1016/j.cmet.2023.06.011.

Inflammation and cholesterol at the crossroads of vascular risk

Subodh Verma  1 , C David Mazer  2 , Kim A Connelly  3
Affiliations
Free article
Comment

Inflammation and cholesterol at the crossroads of vascular risk

Subodh Verma et al. Cell Metab. .
Free article

Abstract

Although the role of inflammation in atherosclerosis is established, whether this relationship remains important after lowering low-density lipoprotein cholesterol (LDL-C) is still unclear. Recently in The Lancet, Ridker et al. demonstrated that residual inflammatory risk was a stronger predictor of fatal and non-fatal events compared to residual cholesterol risk, supporting the concept of inflammation testing to guide vascular risk reduction.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.V. is a national leader for the ZEUS trial and reports receiving research grants and/or speaking honoraria from Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Janssen, Novartis, Novo Nordisk, Pfizer, PhaseBio, S&L Solutions, and Sanofi; S.V. is the President of the Canadian Medical and Surgical Knowledge Translation Research Group, a federally incorporated not-for-profit physician organization. C.D.M. reports advisory board honoraria/consulting fees from Amgen, AstraZeneca, BioAge, Biotest, Boehringer Ingelheim, Cytosorbents and PhaseBio and DSMB stipends from Beth Israel Deaconess Medical Center, Cerus, and Takeda. K.A.C. is listed as an inventor on a patent application by Boehringer Ingelheim on the use of dipeptidyl peptidase-4 inhibitors in heart failure and reports receiving research grants to his institution from AstraZeneca, Boehringer Ingelheim, and Servier; support for travel to scientific meetings from Boehringer Ingelheim; and honoraria for speaking engagements and ad hoc participation in advisory boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novartis, Novo Nordisk, and Servier.

Comment on

LinkOut - more resources